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Introduction
Major depression is among the most prevalent and costly disor-
ders and is the third leading cause of disease burden world-
wide.1 Unfortunately, pharmacotherapy is efficacious in only 
two-thirds of patients, even after 4 trials with different drugs,2 
leaving a substantial percentage of patients with transient, partial 
or no responses. Actually, treatment- resistant depression (TRD) 
has an estimated prevalence of 1%–3%,3 which has urged the de-
velopment of new strat egies to overcome the limitations of exist-
ing therapeutic approaches (including pharmacotherapy and 
psychotherapy). Among these novel strategies, deep brain stimu-
lation (DBS) has been successfully used in patients with TRD.
Deep brain stimulation is a stereotactic functional neuro-
surgery technique that consists of the implantation of elec-
trodes connected to a neurostimulator in different brain areas 
related to the given disease. New applications of this tech-
nique are being explored in some patients with treatment- 
resistant psychiatric illnesses, such as treatment-resistant 
 obsessive–compulsive and major depressive disorders.3
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Background: To date, antidepressant drugs show limited efficacy, leaving a large number of patients experiencing severe and persist-
ent symptoms of major depression. Previous open-label clinical trials have reported significant sustained improvements with deep brain 
stimu lation (DBS) of the subcallosal cingulate gyrus (SCG) in patients with severe, chronic treatment-resistant depression (TRD). This 
study aimed to confirm the efficacy and measure the impact of discontinuation of the electrical stimulation. Methods: We conducted a 
6-month double-blind, randomized, sham-controlled crossover study in implanted patients with previous severe TRD who experienced 
full remission after chronic stimulation. After more than 3 months of stable remission, patients were randomly assigned to 2 treatment 
arms: the ON–OFF arm, which involved active electrode stimulation for 3 months followed by sham stimulation for 3 months, and the 
OFF–ON arm, which involved sham stimulation for 3 months followed by active stimulation for 3 months. The primary outcome measure 
was the difference in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score between sham and active stimulation. 
 Results: We enrolled 5 patients in our trial. A Friedman repeated-measures analysis of variance revealed a significant effect of treat-
ment (c21 = 5.0, p = 0.025) in patients with higher depression scores during sham stimulation. At the end of active stimulation, depression 
was remitted in 4 of 5 patients and none of them had experienced a relapse, whereas at the end of sham stimulation, 2 patients re-
mained in remission, 2 relapsed and 1 showed a progressive worsening without reaching relapse criteria. Limitations: The small sample 
size limited the statistical power and external validity. Conclusion: These preliminary findings indicate that DBS of the SCG is an effect-
ive and safe treatment for severe forms of TRD and that continuous electrical stimulation is required to maintain therapeutic effects. Trial 
registration: NCT01268137 (ClinicalTrials.gov).
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The use of DBS for TRD has been attempted in different 
brain targets, showing promising and encouraging results.4–8 
To date, the findings support the efficacy of the technique in 
the subcallosal cingulate gyrus (SCG),6,7,9 the nucleus accum-
bens10,11 and the ventral capsule/ventral striatum.12 Although 
these previous studies express agreement with even the long-
term safety and antidepressant efficacy of DBS in TRD, data 
have been obtained using uncontrolled or open-label de-
signs.5 Given the complexity of the procedure, it is still un-
clear whether the antidepressant response to DBS can be 
fully attributed to electrode stimulation, to local changes due 
to the implantation of metal electrodes with eventual altera-
tions of network function or, less likely, to placebo effects. 
Hence, controlled studies with experimental validity are 
needed to clarify the role of the different interventions in the 
antidepressant response to DBS.
Here we report on, to our knowledge, the first double-blind, 
randomized, sham-controlled crossover study conducted to 
confirm the efficacy and measure the effect of discontinuation 
of electrical stimulation of the SCG in a group of patients with 
TRD who achieved full remission after continuous DBS.
Methods
Patients
A sample of depressed patients with a severe and highly re-
sist ant form of major depression, refractory to multiple antide-
pressant drug trials, psychotherapy or electroconvulsive ther-
apy, was selected for DBS of the SCG (details of the surgical 
procedure and sample have been published previously7). After 
discharge from the Neurosurgery ward, patients remained in 
the Psychiatry ward for 2 days and were then followed by 
their psychiatrist (R.P.E.) in the outpatient clinic.
Patient recruitment occurred between February 2008 and 
December 2009. To be included in the present trial, implanted 
patients had to achieve stable clinical remission with continu-
ous stimulation. Stable clinical remission was defined a 17-
item Hamilton Rating Scale for Depression (HAMD-17) score 
below the cut-off of 8, maintained for at least 3 months.
The trial was conducted in the Department of Psychiatry of 
the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, in 
accordance with the Declaration of Helsinki. The ethics commit-
tee of the hospital approved our study protocol, and all patients 
gave written informed consent. The clinical trial was also ap-
proved by the Agencia Española de Medicamentos y Productos 
Sanitarios (Spanish regulatory drug agency). The protocol is 
regis tered at ClinicalTrials.gov with the identifier NCT01268137.
Study design
Our study was a randomized, double-blind, controlled cross-
over clinical trial with a total duration of 6 months compris-
ing 2 consecutive 3-month phases. After a stable clinical re-
sponse to DBS, patients were randomly assigned to 1 of 2 
arms: the OFF–ON arm, which involved sham stimulation 
for 3 months followed by active stimulation for 3 months, or 
the ON–OFF arm, which involved active stimulation for 
3  months followed by sham stimulation for 3 months. We 
generated the random allocation sequence using the pseudo-
random numbers generator in SPSS software version 18. 
Given the small number of patients, no blocking was used. 
Random assignment was done with sealed envelope selec-
tion to conceal the sequence from the rest of the researchers 
and to ensure that only the investigator who manipulated the 
neurostimulator (A.G.) knew the allocation pertaining to 
each individual. This investigator did not carry out any as-
sessment or any other intervention during the trial period. 
Given the small number of patients who could be included 
and randomly assigned, we performed no power calculations 
to determine sample size.
For each individual, the following stimulation parameters 
were maintained during the active stimulation periods of the 
trial and after the trial: frequency 130–135 Hz, amplitude 
3.5–5 V and pulse width 120–240 ms. Although pulse widths 
were higher in our group, most values were similar to those 
used in previous studies of SCG DBS for depression.4,6,9 In the 
case of 2 visits in which HAMD-17 scores above 14 were re-
corded, patients were withdrawn, the stimulator was turned 
on (for patients in the sham stimulation phase), or the stimu-
lation parameters were adjusted (for patients in the active 
stimulation phase). Clinical assessments were performed 
 every 2 weeks by a single psychiatrist (R.P.E.), who was un-
aware of the stimulation assignment. Concurrent antidepres-
sant medication was held constant during the trial, and it 
was adjusted at the end of the trial, if necessary.
Outcome measures and data analyses
The primary outcome measures were the HAMD-17 scores in 
each month of the trial (although patients were visited at least 
twice a month during this 6-month period). The HAMD-17 
scores while on sham stimulation were combined and those 
while on active stimulation were combined, and then the scores 
were averaged per treatment to carry out the main analysis. 
Given the small sample, we used Friedman nonparametric, 
 repeated-measures analysis of variance (ANOVA) to compare 
active and sham stimulation. We calculated the areas under the 
curve (AUC) of HAMD-17 scores for active and sham stimula-
tion during the 2 phases of the trial using a trapezoid method, 
which is a common approximation of an area under a set of ad-
joining straight line segments. Missing values were replaced 
 using the last observation carried forward method. We consid-
ered results to be significant at p < 0.05.
Rates of remission and relapse were also calculated. Remis-
sion was defined as a HAMD-17 score lower than 8, and re-
lapse was defined as a worsening of depressive symptoms 
with a HAMD-17 score higher than 14.
Results
In December 2009, 8 patients had received implants for DBS 
(6 women and 2 men). Figure 1 shows the study selection pro-
cess and final sample. Five of 8 patients achieved stable clinical 
remission with DBS of the SCG and were then enrolled and 
completed the present trial. Two patients were allocated to the 
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OFF–ON arm, and 3 to the ON–OFF arm. One patient (pa-
tient 4, ON–OFF arm) was withdrawn from the trial during the 
OFF phase because of a serious relapse. Another patient (pa-
tient 1, OFF–ON arm) also experienced a severe relapse by the 
end of the OFF phase, but there was no need to withdraw this 
patient. Sample characteristics are shown in Table 1. The sever-
ity of clinical symptoms and the demographic characteristics at 
trial initiation did not differ between the 2 treatment arms (all 
p > 0.21). Table 2 provides information on patient allocation, 
stimulating parameters and active electrodes at the beginning 
of the trial as well as pharmacological treatment at trial entry. 
No antidepressant medication changes were required, which 
avoided potential confounding factors on DBS efficacy. In addi-
tion, Figure 2 displays the location of electrodes in the SCG.  
The Friedman repeated-measures ANOVA revealed a sig-
nificant effect of treatment (c21 = 5.0, p = 0.025), with higher 
depression scores during sham stimulation (HAMD-17 
scores for each participant averaged over 3 months). The re-
sulting AUC of HAMD-17 scores for patients subjected to ac-
tive and sham stimulation were 13.9 and 16.3, respectively, 
during the first phase and 5.0 and 20.8, respectively, during 
the second phase of the trial (Fig. 3).
During active stimulation, 4 of 5 patients maintained re-
sponse scores, and at the end of the active phase none of 
them had relapsed (4 were remitted patients; Fig. 4). Con-
versely, during sham stimulation, only 2 patients remained 
in remission, another 2 relapsed and 1 showed a progressive 
worsening without reaching relapse criteria.
Fig. 1: Study selection for the randomized controlled clinical trial. LOCF = last observation carried forward; OFF–ON = 3 mo of sham stimula-
tion followed by 3 mo of active stimulation; ON–OFF = 3 mo of active stimulations followed by 3 mo of sham stimulation.
Assessed for eligibility (n = 33)
Excluded (n = 25)
Not meeting inclusion criteria (n = 21)
Declined to be implanted (n = 2)
Other reasons (n = 2)
Implanted patients (n = 8)
Randomized (n = 5)
Allocated to OFF–ON arm (n = 2) Allocated to ON–OFF arm (n = 3)
Analyzed (n = 2)
Analyzed (n = 3)
LOCF
Discontinued for relapse (n = 1)
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Incidents and adverse events
No other neuropsychiatric complications or general adverse 
effects (e.g., headache, dizziness, gastrointestinal disturbances, 
paresthesias) associated with stimulation were identified dur-
ing the clinical trial period. Adverse events associated with the 
device or surgery and those that took place before randomiza-
tion were few and have been described elsewhere.7
Discussion
The results of this first double-blind, randomized, controlled 
crossover clinical trial indicate that DBS of the SCG may be 
an effective and safe treatment for patients with severe forms 
of depression and confirm that continuous electrical stimula-
tion is required to maintain therapeutic effects. The overall 
clinical impression at the end of the study was that antide-
pressant response to DBS is lost after cessation of the stimula-
tion, as we observed clear relapses or clinical worsening after 
discontinuation. Previous clinical trials of DBS of the SCG in 
patients with TRD were uncontrolled or open label.4–7 Some 
prior studies reported relapses after accidental DBS cessation 
(e.g., battery depletion6), and only 1 trial attempted to incor-
porate a single-blind discontinuation phase, which was inter-
rupted early owing to patient safety concerns.5 Despite grow-
ing evidence in support of DBS of the SCG for TRD, a 
double-blind, sham-controlled study with maximal safety 
guaranties was strongly needed to dispel doubts about the 
efficacy of the treatment and to corroborate the importance of 
maintaining electrical stimulation.
Table 2. Patient data on randomization, active contacts and stimulating parameters at the beginning of the trial and the medications 
prescribed at trial entry
Patient Trial arm Active electrodes Stimulation parameters Pharmacological treatment
Patient 1 OFF-ON L 0(–) 2(+) 
R 4(–) 6(+)
A = 4.5 V
D = 210 μs
F = 135 Hz
Duloxetine (120 mg/d)
Quetiapine (1000 mg/d)
Lorazepam (2 mg/d)
Patient 2 ON-OFF L 0(–) 3(+)
R 4(–) 7(+)
A = 5 V
D = 180 μs
F = 135 Hz
Venlafaxine (300 mg/d)
Mirtazapine (60 mg/d)
Lithium (400 mg/d)
Diazepam (30 mg/d)
Quetiapine (200 mg/d)
Patient 3 ON-OFF L 0(–) 1(+)
R 5(–) 6(+)
A = 5 V
D = 180 μs
F = 135 Hz
Duloxetine (90mg/d)
Mirtazapine (30mg/d)
Olanzapine (5mg/d)
Diazepam (50mg/d)
Alprazolam (6mg/d)
Zolpidem (10mg/d)
Levomepromazine (50 mg/d)
Pregabaline (300mg/d)
Patient 4 ON-OFF L 0(–) 1(+)
R 4(–) 5(+)
A = 4 V
D = 180 μs
F = 135 Hz
Duloxetine (120 mg/d)
Mirtazapine (60 mg/d)
Valproate (1500 mg/d)
Trazodone (200 mg/d)
Lorazepam (5mg/d)
Midazolam (7.5 mg/d)
Patient 5 OFF-ON L 0(–) 2(+)
R 4(–) 6(+)
A = 3.5 V
D = 120 μs
F = 135 Hz
Imipramine (100 mg/d)
Medazepam (10 mg/d)
A = amplitude; D = pulse width; F = frequency; L = left electrode; OFF–ON = 3 mo of sham stimulation followed by 3 mo of active stimulation; ON–OFF = 3 mo of 
active stimulations followed by 3 mo of sham stimulation; R = right electrode.
Table 1. Clinical and demographic characteristics of the study 
sample (n = 5)
Group, mean ± SD
Characteristic OFF–ON, n = 2 ON–OFF, n = 3
Age at surgery, yr 42.0 ± 9.9 50.7 ± 14.3
Age at MDD onset, yr 27.5 ± 0.7 20.3 ± 2.5
No. of previous episodes 3.5 ± 0.7 7.3 ± 6.1
No. of previous hospitalizations 6.5 ± 7.7 8.7 ± 8.1
MADRS
Prerandomization 2.0 ± 2.8 3.4 ± 2.5
First month 2.0 ± 1.4 9.4 ± 10.7
Second month 11.5 ± 2.1 8.4 ± 2.8
Third month 8.5 ± 12.0 7.7 ± 4.5
Fourth month 2.0 ± 2.8 9.7 ± 10.7
Fifth month 2.0 ± 2.8 15.4 ± 6.5
Sixth month 2.0 ± 2.8 14.0 ± 8.5
End point 4.0 ± 0.7 5.7 ± 2.1
HAMD-17
Prerandomization 3.5 ± 2.1 3.7 ± 2.3
First month 6.0 ± 8.5 8.7 ± 1.2
Second month 9.0 ± 4.2 6.0 ± 2.0
Third month 8.5 ± 12.0 7.0 ± 5.6
Fourth month 3.0 ± 1.4 7.7 ± 7.4
Fifth month 2.5 ± 2.1 11.3 ± 5.0
Sixth month 2.0 ± 2.8 11.3 ± 5.0
End point 3.5 ± 0.7 5.3 ± 1.2
HAMD-17 = 17-item Hamilton Rating Scale for Depression; MADRS = Montogomery-
Åsberg Depression Rating Scale; MDD = major depressive disorder; OFF–ON = 3 mo 
of sham stimulation followed by 3 mo of active stimulation; ON–OFF = 3 mo of active 
stimulations followed by 3 mo of sham stimulation; SD = standard deviation.
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Individuals included in our trial were patients with highly 
refractory depression who had experienced a sustained remis-
sion with chronic DBS of the SCG. The most interesting obser-
vation of the present study is that almost all patients main-
tained remission during the active stimulation phase, and 
none of them experienced a relapse, whereas 3 of 5 relapsed or 
worsened with the cessation of stimulation, indicating a direct 
therapeutic effect of active DBS. Given the blinded and con-
trolled conditions of the trial and the fact that enrolled patients 
had attained a sustained remission with continuous DBS be-
fore entering the trial, our findings do not seem to be due to 
placebo effects. It is worth mentioning that the duration of the 
clinical stability before trial enrolment, which ranged from 3 to 
9 months (mean 6.2 mo), was long enough that relapses could 
be considered a consequence of the treatment arms.
The unexpected moderate worsening (mostly owing to anx-
iety items) during the initial phase of the ON–OFF arm (i.e., ac-
tive stimulation) may be a random difference due to the small 
number of patients in each treatment arm. Alternatively, it could 
also reflect a modest nocebo effect mediated by negative expec-
tations when patients faced the possibility of being randomly as-
signed to the sham stimulation. This hypothesis seems particu-
larly plausible with these patients, who had achieved complete 
remission with DBS after years of severe depression. However, 
symptomatic exacerbation among these patients was more con-
spicuous when they entered the OFF phase of the trial. The role 
of negative expectations has been described previously in pa-
tients with Parkinson disease who were successfully treated 
with DBS of the subthalamic nucleus.13,14 Benedetti and col-
leagues13 showed that motor performance worsened not only 
Fig. 2: Location of electrode contacts on a sagittal view of the cingulate gyrus. Circles are schematic representations of electrode contacts (“+” 
indicates positive contacts and “–” indicates negative contacts). Numbers within circles correspond to each patient. Details of stimulating par-
ameters are given in Table 2.
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Fig. 3: Mean change in depression scores based on the 17-item 
Hamilton Rating Scale for Depression (HAMD-17) for the ON–OFF 
(3 mo active followed by 3 mo sham) group and the OFF–ON (3 mo 
sham followed by 3 mo active) group.
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when stimulation was turned off, but also when researchers 
simply pretended to disconnect the device. Whatever the expla-
nation of the initial worsening in our sample, it had a small ef-
fect size and was transient, allowing the detection of significant 
differences between active and sham simulation phases. Despite 
the group differences during these phases, some patients did 
not experience any clinical change when the stimulation was 
turned off. Mayberg and colleagues6 also reported a case in 
which antidepressant effects were maintained up to 4 weeks af-
ter a single-blinded discontinuation of the electrical stimulation. 
Both observations suggest the existence of long-lasting thera-
peutic effects of DBS in some depressed patients.
Deep brain stimulation is still unproven and has limited ap-
proval by the United States Food and Drug Administration or 
the European Medicines Agency for treating psychiatric condi-
tions, such as major depression, obsessive– compulsive disor-
der and Tourette syndrome. In the case of depression, because 
of heterogeneous patient characteristics and the limited num-
ber of studies available — few of them with adequate de-
sign — there is a strong need to keep acquiring data to deter-
mine the effectiveness/efficacy of the intervention and what 
brain targets and clinical profiles of patients are the most opti-
mal. A key question, which we addressed in the present study, 
is whether the active stimulation of electrodes is essential to 
achieve therapeutic effects. To our knowledge, until now, only 
1 previous trial has assessed the efficacy of DBS for TRD using 
a double-blinded randomized design. The selected target was 
the ventral  capsule/ventral striatum, patients were random-
ized early after surgery, and the findings were negative (data 
presented at the 67th Annual Scientific Convention & Program 
of the Society of Biological Psychiatry15). By contrast, a double-
blind crossover design allowed us to test the efficacy of DBS of 
the SCG in patients who had already responded, providing re-
liable information on the causal relation of stimulation effects 
Fig. 4: Individual changes on th 17-item Hamilton Rating Scale for Depression (HAMD-17) scores during active stimulation (ON) 
and sham stimulation (OFF) periods. Scores on the dark grey background represent relapses; scores on the white background 
correspond to remissions.
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with minimum risks for the patient (i.e., a putative worsening 
of patients after switching off electrodes was carefully as-
sessed, and, in the occurrence of a relapse, the patient was 
withdrawn and stimulation adjusted or restarted).
Neuroimaging studies indicate that the SCG plays an im-
portant role in the pathophysiology and treatment of major 
depression.17-19 Indeed, the prefrontal cortex is the higher or-
der association cortex, integrating sensory, limbic and auto-
nomic information.16 It plays a major role in higher brain 
functions, exerting a top–down control of a large number of 
cortical and subcortical structures.17 In particular, the SCG 
cortex is anatomically and functionally related with other 
cortical, thalamic and limbic areas.18,20,21 Since DBS affects 
multiple neural structures, such as myelinated axons and, to 
a lesser extent, cell bodies,22 it is likely that the orthodromic 
and antidromic axonal stimulation of the SCG may affect 
neuronal transmission in a large number of brain areas pro-
jecting to and receiving inputs from this key area. In agree-
ment with this view, focal and distal effects can be inferred 
after DBS of the SCG,8 and this could explain why some pa-
tients with depression can still maintain their previous im-
provement in the sham stimulation phase and also why the 
effects are not immediate when stimulation is activated.
Limitations
Unfortunately, the very small sample size represents a major 
limitation of the study, so figures should be considered sup-
portive, and statistical analyses are essentially illustrative 
rather than definitive. Given that only patients in a steady 
state of remission were randomized, the conclusions should 
be drawn with some caution owing to possible selection bias. 
In any case, 5 of 8 patients could be randomly assigned to a 
trial arm, which is a remarkable proportion of patients for 
such extremely chronic, treatment-resistant disorders. The 
findings of prior works by others4–6,9 and by our group,7 ob-
tained with independent samples, support the benefits of 
DBS of the SCG even for patients who have not attained com-
plete remission. However, the risk of clinical aggravation af-
ter interruption of stimulation in patients with severe resid-
ual symptoms was considered unjustifiable. 
Another limitation concerns the assessment measures, be-
cause current rating scales, such as the HAMD-17, may not 
be able to wholly capture the beneficial effects of the inter-
vention. This could have underestimated the effect of elect-
rical stimulation.23 These authors also point out that some be-
havioural changes induced by DBS, such as increased 
emotional expression, sociability or the increase of daily ac-
tivities, may not lead to a clinically important decrease in the 
rating scale scores. Finally, a 3-month period may be insuffi-
cient to fully dissipate carryover effects (i.e., therapeutic ben-
efits could persist in some patients during sham stimulation, 
and slow gradual improvements could occur after DBS re-
initiation). A longer period would have probably heightened 
differences in favour of the intervention, but it would have 
been unacceptable for ethical and safety concerns. In light of 
our results, 3 months seems adequate to reliably test the ef-
fects of stimulation of the SGC in patients with TRD.
Conclusion
Given the trial design, the overall benefits of the present 
study overcome the potential harmful effects of switching 
off the electrodes. At this point, the present study consti-
tutes, to our knowledge, the first trial of DBS in patients 
with TRD using a sham-controlled discontinuation phase. 
The findings, obtained in a very small sample, highlight the 
necessity for larger studies, even combining other data sets 
with similar brain targets. This would help to confirm the 
results presented herein and to ascertain useful predictors 
of DBS response in patients with depression.
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